Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 644

1.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

2.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

3.

The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.

Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung KYY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, de Wit M, Wulffraat N, van de Laar MAFJ, Vonkeman HE.

Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23799. [Epub ahead of print]

PMID:
30358135
4.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

5.

Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis.

Mahler EAM, den Broeder AA, den Broeder N, Bijlsma JWJ, Snijders GF, van den Hoogen FHJ, van den Ende CHM.

Clin Exp Rheumatol. 2018 Sep 17. [Epub ahead of print]

PMID:
30299244
6.

World Arthritis Day 2018 - Perspectives on Rheumatic musculoskeletal diseases.

Radstake TRDJ, McInnes IB, Bijlsma JWJ.

Eur J Immunol. 2018 Oct;48(10):1604-1606. doi: 10.1002/eji.201870125. No abstract available.

PMID:
30285288
7.

Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.

Abhishek A, Iagnocco A, Bijlsma JWJ, Doherty M, Lioté F.

RMD Open. 2018 Sep 21;4(2):e000743. doi: 10.1136/rmdopen-2018-000743. eCollection 2018.

8.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
9.

RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers.

Cuppen BVJ, Rossato M, Fritsch-Stork RDE, Concepcion AN, Linn-Rasker SP, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Radstake TR; all SRU investigators.

Expert Rev Clin Immunol. 2018 Jul;14(7):623-633. doi: 10.1080/1744666X.2018.1480937. Epub 2018 Jun 6.

PMID:
29808722
10.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
11.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

12.

Disease activity and dropout in young persons with juvenile idiopathic arthritis in transition of care: a longitudinal observational study.

van Pelt PA, Dolhain RJEM, Kruize AA, Ammerlaan JJW, Hazes JW, Bijlsma JWJ, Wulffraat NM.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):163-168. Epub 2018 Jan 31.

PMID:
29461957
13.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
14.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
15.

Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al.

Safy M, Jacobs JWG, Ijff ND, Bijlsma JWJ, van Laar JM, de Hair MJH; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2018 Aug;77(8):e48. doi: 10.1136/annrheumdis-2017-212380. Epub 2017 Oct 9. No abstract available.

PMID:
28993345
16.

Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases.

Mahler EAM, Boers N, Bijlsma JWJ, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

J Rheumatol. 2018 Jan;45(1):122-127. doi: 10.3899/jrheum.170181. Epub 2017 Aug 15.

PMID:
28811352
17.

Will we ever have better glucocorticoids?

Buttgereit F, Bijlsma JWJ, Strehl C.

Clin Immunol. 2018 Jan;186:64-66. doi: 10.1016/j.clim.2017.07.023. Epub 2017 Jul 27.

PMID:
28757452
18.

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Pethö-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ.

Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x.

19.

A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.

Rubbert-Roth A, Jacobs JWG, Bijlsma JWJ, Welsing PMJ.

Ann Rheum Dis. 2018 Jul;77(7):1085-1086. doi: 10.1136/annrheumdis-2017-211485. Epub 2017 Jun 23. No abstract available.

PMID:
28646081
20.

Managing rheumatic and musculoskeletal diseases - past, present and future.

Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB.

Nat Rev Rheumatol. 2017 Jul;13(7):443-448. doi: 10.1038/nrrheum.2017.95. Epub 2017 Jun 15. Review.

PMID:
28615732

Supplemental Content

Loading ...
Support Center